Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

With hemophilia, it's easy to assume that joint pain is caused by bleeding. But that's not always the case, columnist G ...

Using “cure” to refer to “obtaining a normal life” also fits — if you ignore previously lost education, career opportunities ...

The study shows that 94% of patients eliminated factor IX prophylaxis and maintained near-normal factor IX levels through ...

Columnist Alliah Czarielle doesn't want a person with an invisible disability to be perceived by businesses as a fraud.

CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...